BTIG lowered the firm’s price target on Haemonetics (HAE) to $84 from $88 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $64 from $70 at Citi
- Haemonetics: FDA Label Expansion and New Product Launches Poised to Reignite Vascular Closure Growth by FY27
- Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
- Haemonetics price target lowered to $70 from $75 at Citi
- Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure